These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7554807)

  • 1. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN; Erwin ME; Barrett MS
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG; Erwin MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN; Johnson DM; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.
    Jones RN; Aldridge KE; Barry AL; Fuchs PC; Gerlach EH; Pfaller MA; Washington JA
    Diagn Microbiol Infect Dis; 1988 Aug; 10(4):221-40. PubMed ID: 3072151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.
    Jones RN
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):167-70. PubMed ID: 7874885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of a fluoroquinolone-class disk for susceptibility tests.
    Barry AL; Fuchs PC
    Am J Med; 1993 Mar; 94(3A):17S-22S. PubMed ID: 8383918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
    Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
    Pfaller MA; Jones RN; Washington JA; Koontz FP; Gerlach EH; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):145-50. PubMed ID: 1315231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the emergence of resistance to lomefloxacin in vitro.
    Kanematsu M; Greenwood D
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):741-5. PubMed ID: 2506046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
    Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of lomefloxacin (SC-47111) and other quinolones.
    Sun ZM; Maskell JP; Sehgal SC; Williams JD
    Infection; 1989; 17(3):165-7. PubMed ID: 2737760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial and plasmid curing activity of lomefloxacin in vitro.
    Derlot E; Poyart-Salmeron C; Courvalin P
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1048-52. PubMed ID: 2515963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ten-laboratory study of lomefloxacin (NY-198 or SC 47111) antimicrobial activity in Argentina.
    Bianchini HN; Sarachian B; Fernandez A; Paolasso R; Kaufman C; Notario R; Porven G; Ingaramo RA; Perez S; Ferrero SM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):45S-50S. PubMed ID: 2676328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.